1. Home
  2. VSTS vs QURE Comparison

VSTS vs QURE Comparison

Compare VSTS & QURE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Vestis Corporation

VSTS

Vestis Corporation

HOLD

Current Price

$10.04

Market Cap

1.0B

Sector

N/A

ML Signal

HOLD

Logo uniQure N.V.

QURE

uniQure N.V.

HOLD

Current Price

$17.40

Market Cap

1.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
VSTS
QURE
Founded
1936
1998
Country
United States
Netherlands
Employees
N/A
248
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.0B
1.1B
IPO Year
2023
2013

Fundamental Metrics

Financial Performance
Metric
VSTS
QURE
Price
$10.04
$17.40
Analyst Decision
Sell
Buy
Analyst Count
4
14
Target Price
$5.88
$45.00
AVG Volume (30 Days)
974.8K
1.5M
Earning Date
05-11-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
29.67
EPS
N/A
N/A
Revenue
$2,734,839,000.00
$13,107,000.00
Revenue This Year
N/A
$126.12
Revenue Next Year
$1.67
$200.43
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.98
$8.73
52 Week High
$10.29
$71.50

Technical Indicators

Market Signals
Indicator
VSTS
QURE
Relative Strength Index (RSI) 80.19 52.12
Support Level $7.24 $13.47
Resistance Level N/A $18.37
Average True Range (ATR) 0.35 1.41
MACD 0.20 0.26
Stochastic Oscillator 90.54 70.60

Price Performance

Historical Comparison
VSTS
QURE

About VSTS Vestis Corporation

Vestis Corp is a provider of uniform rentals and workplace supplies across the United States and Canada. It provides uniforms, mats, towels, linens, restroom supplies, first-aid supplies, safety products, and other workplace supplies. The Company serves customers ranging from small, family-owned operations with a single location to large corporations and national franchises with multiple locations. The company operates in the United States and Canada as reportable segments. The company earns the majority of its revenue from the United States.

About QURE uniQure N.V.

uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases. Its program and pipeline involves: Huntington's Disease, Temporal Lobe Epilepsy (TLE), Fabry Disease, ALS (SOD1), Hemophilia B, Clinical Trials, and Research Programs.

Share on Social Networks: